PlainRecalls
FDA Drug Moderate Class II Terminated

Cefdinir for Oral Suspension USP, 250 mg/5mL, packaged in 60 mL bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India, NDC 68180-723-20

Reported: July 29, 2020 Initiated: July 2, 2020 #D-1406-2020

Product Description

Cefdinir for Oral Suspension USP, 250 mg/5mL, packaged in 60 mL bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India, NDC 68180-723-20

Reason for Recall

Superpotent Drug: Out-of-specification (OOS) result observed in an assay test of retention samples.

Details

Units Affected
35,928 bottles
Distribution
U.S.A. Nationwide
Location
Baltimore, MD

Frequently Asked Questions

What product was recalled?
Cefdinir for Oral Suspension USP, 250 mg/5mL, packaged in 60 mL bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India, NDC 68180-723-20. Recalled by Lupin Pharmaceuticals Inc.. Units affected: 35,928 bottles.
Why was this product recalled?
Superpotent Drug: Out-of-specification (OOS) result observed in an assay test of retention samples.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 29, 2020. Severity: Moderate. Recall number: D-1406-2020.